---
title: Young Breast Cancer Cohort Study
nct_id: NCT03131089
overall_status: UNKNOWN
sponsor: Samsung Medical Center
study_type: OBSERVATIONAL
primary_condition: Breast Cancer
countries: South Korea
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03131089.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03131089"
ct_last_update_post_date: 2017-04-27
last_seen_at: "2026-05-12T06:50:58.685Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Young Breast Cancer Cohort Study

**Official Title:** Prospective Cohort Study for Development of Personalized Treatment Strategy Based on Biologic Tumor Behavior and Clinical Characteristics in Young Breast Cancer (YBC) Patients

**NCT ID:** [NCT03131089](https://clinicaltrials.gov/study/NCT03131089)

## Key Facts

- **Status:** UNKNOWN
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 2000
- **Lead Sponsor:** Samsung Medical Center
- **Conditions:** Breast Cancer
- **Start Date:** 2013-04-11
- **Completion Date:** 2023-04-10
- **CT.gov Last Update:** 2017-04-27

## Brief Summary

This study is prospective cohort study to investigate and identify comprehensively the clinicopathological features and long-term outcome of young breast cancer (YBC).

We have enrolled Breast cancer patients under 40 year-old and collected their baseline characteristics including tumor character, familiar history and other background information. Moreover, we have collected breast cancer tissue/blood sample for analyzing genetic characteristics, if patient agree to genetic analysis.

## Eligibility

- **Maximum age:** 40 Years
- **Sex:** FEMALE
- **Healthy Volunteers:** No

```
Inclusion Criteria:

1. Diagnosis with breast cancer
2. Age under 40 year-old or diagnosis with breast cancer at pregnancy or within 1year after delivery
3. Obtained informed consent form

Exclusion Criteria:

1\) Cannot understand or disagree to informed consent form
```

## Primary Outcomes

- **Progression free survival** _(time frame: From date of surgery until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months)_ — Time to detect disease recurrence from surgery date

## Locations (1)

- Samsung Medical Center, Seoul, South Korea — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.samsung medical center|seoul||south korea` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT03131089.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT03131089*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*